An Innovative Therapy for Inflammatory Diseases

We are a bio-tech company established in 2000 (listed on KOSDAQ), composed of three business sectors: biopharmaceuticals. API and water solutions &
anti-microbials.

In biopharmaceuticals sector, INVOSSA-K, a non-invasive allogeneic cell and gene therapy for osteoarthritis, is the most advanced product which was approved by Korea's Ministry of Food and Drug Safety and launched in Korea since November 2017 (US Phase III is ongoing).

Our company has successfully signed contracts of INVOSSA-K for out-licensing in Japan and distribution in Hong Kong & Macau, Saudi Arabia & UAE, Mongolia, China's Hainan Province, Southeast Asia, Australia and New Zealand.

At the present, we have three gene therapy drug candidates: KLS-2031 for neuropathic pain (IND approval in Mar 2019), KLS-3020 for oncolytic virus and KLS-1010 for cancer vaccine.